Annovis Bio financials
$1.30−5.80%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$14.4M | -$18.0M | -$9.7M | -$7.4M | -$6.3M | -$6.3M | -$6.7M | -$4.4M | -$7.8M | -$7.8M | -$10.4M | -$14.9M |
| Net income | -$14.8M | -$17.6M | -$9.8M | -$7.3M | -$6.2M | -$5.5M | -$5.9M | -$12.6M | -$5.0M | -$1.1M | -$22.2M | -$14.7M |
| Net margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-0.40 | $-0.63 | $-0.38 | $-0.37 | $-0.32 | $-0.32 | $-0.42 | $-0.97 | $-0.44 | $-0.72 | $-2.24 | $-1.63 |
| EBITDA | -$14.4M | -$18.0M | -$9.7M | -$7.4M | -$6.3M | -$6.3M | -$6.7M | -$4.4M | -$7.8M | -$7.8M | -$10.4M | -$14.9M |
| Operating cash flow | -$21.9M | -$9.0M | -$8.9M | -$3.5M | -$5.1M | -$8.1M | -$8.3M | -$3.2M | -$3.4M | -$7.0M | -$9.4M | -$9.4M |
| Free cash flow | -$21.9M | -$9.0M | -$8.9M | -$3.5M | -$5.1M | -$8.1M | -$8.3M | -$3.2M | -$3.4M | -$7.0M | -$9.4M | -$9.4M |
| Diluted shares | 37.5M | 27.8M | 25.6M | 19.7M | 19.5M | 17.4M | 13.8M | 13.0M | 11.3M | 10.8M | 9.9M | 9.0M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $18.7M | $14.2M | $19.5M | $15.3M | $17.1M | $22.2M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $22.0M | $16.2M | $21.1M | $17.2M | $21.5M | $26.7M |
| Total liabilities | $26.3M | $13.1M | $4.2M | $4.0M | $3.1M | $2.7M |
| Shareholders' equity | -$4.3M | $3.1M | $16.9M | $13.2M | $18.3M | $24.1M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology